Mass. life science stocks plunge on prospect of RFK Jr. as HHS head
| ALNY Stock | USD 250.98 6.09 2.49% |
Slightly above 55% of Alnylam Pharmaceuticals' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Alnylam Pharmaceuticals suggests that some traders are interested. Alnylam Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Alnylam Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Alnylam |
Moderna Inc. was among the life sciences companies that saw their stock prices take a nosedive since President-elect Donald Trump named Robert F. Kennedy Jr. as his choice to lead the nations Health and Human Services department.
Read at bizjournals.com
 |
Alnylam Pharmaceuticals Fundamental Analysis
We analyze Alnylam Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alnylam Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alnylam Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Flow From Operations
Cash Flow From Operations Comparative Analysis
Alnylam Pharmaceuticals is currently under evaluation in cash flow from operations category among its peers. Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Alnylam Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Alnylam Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Alnylam Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Alnylam Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Alnylam Pharmaceuticals Related Equities
| AMLX | Amylyx Pharmaceuticals | 7.40 | ||||
| WVE | Wave Life | 4.34 | ||||
| APLS | Apellis Pharmaceuticals | 3.70 | ||||
| INCY | Incyte | 2.51 | ||||
| KRYS | Krystal Biotech | 2.18 | ||||
| EXEL | Exelixis | 2.16 | ||||
| BMRN | Biomarin Pharmaceutical | 1.29 | ||||
| RARE | Ultragenyx | 0.25 | ||||
| BPMC | Blueprint Medicines | 0.30 | ||||
| MDGL | Madrigal Pharmaceuticals | 0.65 | ||||
| UTHR | United Therapeutics | 1.13 | ||||
| DAWN | Day One | 2.19 | ||||
| PRQR | ProQR Therapeutics | 2.21 | ||||
| HALO | Halozyme Therapeutics | 2.47 |
Additional Tools for Alnylam Stock Analysis
When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.